|
|
 |
|
Viewing report
|
|
|
|
Lebanon Pharmaceuticals and Healthcare Report Q2 2010
Business Monitor International, March 2010, Pages: 73
Lebanon Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Lebanon's pharmaceuticals and healthcare industry.
The total pharmaceutical market in Lebanon was worth US$519mn in 2009 and took up 1.71% of GDP, with per-capita spending on medicines at US$123.4. Prescription drug spending was US$460mn, or 89.7% of the total market. Prescription medicines expenditure is forecast to increase as a proportion of the total market, highlighting a rising trend for healthcare usage.
While this can be down to population growth alone, we also believe that access to healthcare services is widening. Patented medicines contributed to 74.8% of the prescription drug market and 67% of the total pharmaceutical sector. Although generic drugs will continue to feature as a small proportion of all pharmaceutical spending, their proportion of the prescription market will rise from 25.2% in 2009 to 30.3% by 2014.
Pharmaceutical industry representatives in Lebanon have announced that drug packaging will be redesigned to enable easy confirmation of product authenticity. The move is part of an effort to address the counterfeit medicines that are infiltrating the country. This follows a region-wide crackdown on counterfeit pharmaceuticals through similar measures, with better regulatory provisions promoted as the most effective measure.
The Order of Pharmacists (OOP) in Lebanon has stated that drug packaging can easily be forged and that new hologram or high-tech identification tags are to be added to medicine labels to make fakes easier to detect. Public enlightenment campaigns have also been underlined as one of the strategies that will deter further purchases and lower demand for these drugs.
The association is also suggesting that pharmacists be positioned at customs and within hospitals to ensure that fake medicines are not unwittingly sold within the national and private healthcare system. Testing laboratories should also be established to ensure that seizures or closures of suspected illegal outlets can be supported with evidence. Imports could also be tested for bioequivalence in this manner, alleviating the reliance on US Food and Drug Administration (FDA)- or European Medicines Agency (EMEA)-derived medicines to ensure product safety.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Lebanon Pharmaceuticals and Healthcare Report Q3 2011
Lebanon Pharmaceuticals and Healthcare Report Q4 2010
Lebanon Pharmaceuticals and Healthcare Report Q1 2009
Lebanon Pharmaceuticals and Healthcare Report Q1 2012
Lebanon Pharmaceuticals and Healthcare Report Q1 2010
Lebanon Pharmaceuticals and Healthcare Report Q3 2008
Lebanon Pharmaceuticals & Healthcare Report Q1 2008
Lebanon Pharmaceuticals and Healthcare Report Q4 2008
United Arab Emirates Pharmaceuticals and Healthcare Report Q1 2011
Kazakhstan Pharmaceuticals and Healthcare Report Q1 2011
|
|
|
|
